BIOGEN INC. Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year
BIOGEN INC. (BIIB) had Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year of $400.00 million as of 2026-03-31, per its 10-Q filed 2026-04-29.
Financial Statements › Notes › Goodwill and Other › Intangible Asset, Finite-Lived, and Capitalized Cost, Software to be Sold, Leased, or Marketed, Estimated Amortization Expense
us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear · last filed 2026-04-29
- 2026-03-31: Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year $400.00M.
- 2025-09-30: Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year $130.00M.
- 2025-06-30: Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year $240.00M.
- 2025-03-31: Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year $350.00M.
| Period end | Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year |
|---|---|
| 2026-03-31 | $400.00M 10-Q · filed 2026-04-29 |
| 2025-09-30 | $130.00M 10-Q · filed 2025-10-30 |
| 2025-06-30 | $240.00M 10-Q · filed 2025-07-31 |
| 2025-03-31 | $350.00M 10-Q · filed 2025-05-01 |
| 2024-09-30 | $125.00M 10-Q · filed 2024-10-30 |
| 2024-06-30 | $185.00M 10-Q · filed 2024-08-01 |
| 2024-03-31 | $265.00M 10-Q · filed 2024-04-24 |
| 2023-09-30 | $75.00M 10-Q · filed 2023-11-08 |
| 2023-06-30 | $110.00M 10-Q · filed 2023-07-25 |
| 2023-03-31 | $165.00M 10-Q · filed 2023-04-25 |
| 2022-09-30 | $55.00M 10-Q · filed 2022-10-25 |
| 2022-06-30 | $130.00M 10-Q · filed 2022-07-20 |
| 2022-03-31 | $200.00M 10-Q · filed 2022-05-03 |
| 2021-09-30 | $70.00M 10-Q · filed 2021-10-20 |
| 2021-06-30 | $110.00M 10-Q · filed 2021-07-22 |
| 2021-03-31 | $165.00M 10-Q · filed 2021-04-22 |
| 2020-09-30 | $60.00M 10-Q · filed 2020-10-21 |
| 2020-06-30 | $126.00M 10-Q · filed 2020-07-22 |
| 2020-03-31 | $193.00M 10-Q · filed 2020-04-23 |
| 2019-09-30 | $65.00M 10-Q · filed 2019-10-22 |
| 2019-06-30 | $130.00M 10-Q · filed 2019-07-24 |
| 2019-03-31 | $200.00M 10-Q · filed 2019-04-24 |
| 2018-09-30 | $91.70M 10-Q · filed 2018-10-23 |
| 2018-06-30 | $215.80M 10-Q · filed 2018-07-24 |
| 2018-03-31 | $330.70M 10-Q · filed 2018-04-24 |
| 2017-09-30 | $106.80M 10-Q · filed 2017-10-24 |
| 2017-06-30 | $222.60M 10-Q · filed 2017-07-25 |
| 2017-03-31 | $346.50M 10-Q · filed 2017-04-25 |
| 2016-09-30 | $92.80M 10-Q · filed 2016-10-26 |
| 2016-06-30 | $181.60M 10-Q · filed 2016-07-21 |
| 2016-03-31 | $265.30M 10-Q · filed 2016-04-21 |
| 2015-09-30 | $94.30M 10-Q · filed 2015-10-21 |
| 2015-06-30 | $185.50M 10-Q · filed 2015-07-24 |
| 2015-03-31 | $269.00M 10-Q · filed 2015-04-24 |
| 2014-09-30 | $104.20M 10-Q · filed 2014-10-22 |
| 2014-06-30 | $217.20M 10-Q · filed 2014-07-23 |
| 2014-03-31 | $316.30M 10-Q · filed 2014-04-23 |
| 2013-09-30 | $113.20M 10-Q · filed 2013-10-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |